Insider Purchases: Inside the Buy
Tag: MedTech
Director Purchases Shares of Johnson & Johnson
A director just slapped fresh cash on Johnson & Johnson stock. With a AAA credit rating, a 100+ year history, blockbuster drugs, cutting-edge MedTech, and a valuation that’s more “fair” than “fire sale,” should retail investors follow—or wait for a better entry point?
AngioDynamics (ANGO)’s CEO Bought Shares a Year Ago and Stock Doubled Since: Will They Keep Going Higher?
AngioDynamics insiders bought low and doubled up, while Wall Street funds practically own the company. With MedTech sales surging and earnings around the corner, can $ANGO climb higher — or will tariffs and volatility zap the gains?
This Wound Care Stock Doesn't Have to Hurt! 🩸🩼
CEO Joseph Capper is buying big. The company’s 9% full-year sales growth and 20%+ EBITDA margins suggest something’s brewing at this placental powerhouse. From PURION™ to profitability—this is wound care with a serious upside.